Literature DB >> 32761300

Cisplatin promotes the expression level of PD-L1 in the microenvironment of hepatocellular carcinoma through YAP1.

Shenghao Li1,2, Jingmin Ji1, Zhiqin Zhang1, Qing Peng1, Liyuan Hao1, Yinglin Guo1, Wenhan Zhou1, Qingzhuo Cui1, Xinli Shi3,4.   

Abstract

Hepatocellular carcinoma (HCC) is one of the most lethal malignancies worldwide. However, the immune tolerance limits the effect of chemotherapeutic drugs. Therefore, the mechanism of cisplatin in promoting PD-L1 expression by YAP1 was investigated in the present study, and we found that cisplatin increased the expression level of YAP1 in the mouse liver with H22 cells. Meanwhile, cisplatin improved the expression level of PD-L1, IL-1β and CCL2 in the tumor microenvironment. Further, cisplatin also enhanced the expression level of YAP1 in shYAP1 HepG2215 cells. The expression of PD-L1 was decreased by Verteporfin, YAP1 inhibitor, during the treatment of DEN/TCPOBOP-induced liver cancer in C57BL/6 mice. These results suggested that cisplatin could deteriorate the immunosuppressive microenvironment through increasing PD-L1, CCL2, IL-1β by upregulated YAP1 expression. Therefore, the study suggested that YAP1 blockade destroyed the immunosuppressive microenvironment of cancer to improve the effect of chemotherapy in HCC.

Entities:  

Keywords:  Cisplatin; Hepatocellular carcinoma; Immunosuppressive microenvironment; PD-L1; YAP1

Mesh:

Substances:

Year:  2020        PMID: 32761300     DOI: 10.1007/s11010-020-03861-0

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  5 in total

1.  Dihydroartemisinin inhibited the Warburg effect through YAP1/SLC2A1 pathway in hepatocellular carcinoma.

Authors:  Qing Peng; Liyuan Hao; Yinglin Guo; Zhiqin Zhang; Jingmin Ji; Yu Xue; Yiwei Liu; Caige Li; Junlan Lu; Xinli Shi
Journal:  J Nat Med       Date:  2022-09-06       Impact factor: 3.192

2.  Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma.

Authors:  Hideki Iwamoto; Takashi Niizeki; Hiroaki Nagamatsu; Kazuomi Ueshima; Takako Nomura; Teiji Kuzuya; Kazuhiro Kasai; Yohei Kooka; Atsushi Hiraoka; Rie Sugimoto; Takehiro Yonezawa; Akio Ishihara; Akihiro Deguchi; Hirotaka Arai; Shigeo Shimose; Tomotake Shirono; Masahito Nakano; Shusuke Okamura; Yu Noda; Naoki Kamachi; Miwa Sakai; Hiroyuki Suzuki; Hajime Aino; Norito Matsukuma; Satoru Matsugaki; Kei Ogata; Yoichi Yano; Takato Ueno; Masahiko Kajiwara; Satoshi Itano; Kunitaka Fukuizumi; Hiroshi Kawano; Kazunori Noguchi; Masatoshi Tanaka; Taizo Yamaguchi; Ryoko Kuromatsu; Atsushi Kawaguchi; Hironori Koga; Takuji Torimura
Journal:  Cancers (Basel)       Date:  2021-02-05       Impact factor: 6.639

3.  Knockdown of lncRNA LINC01234 Suppresses the Tumorigenesis of Liver Cancer via Sponging miR-513a-5p.

Authors:  Wen Xu; Kesang Li; Changfeng Song; Xiaotong Wang; Yueqi Li; Baixue Xu; Xin Liang; Wanli Deng; Junqing Wang; Jianwen Liu
Journal:  Front Oncol       Date:  2020-10-16       Impact factor: 6.244

Review 4.  Improving Anti-PD-1/PD-L1 Therapy for Localized Bladder Cancer.

Authors:  Florus C de Jong; Vera C Rutten; Tahlita C M Zuiverloon; Dan Theodorescu
Journal:  Int J Mol Sci       Date:  2021-03-10       Impact factor: 5.923

5.  Deubiquitinase ubiquitin-specific peptidase 10 maintains cysteine rich angiogenic inducer 61 expression via Yes1 associated transcriptional regulator to augment immune escape and metastasis of pancreatic adenocarcinoma.

Authors:  Xun Liu; Bobo Chen; Jiahui Chen; Zuoyuan Su; Shaolong Sun
Journal:  Cancer Sci       Date:  2022-04-05       Impact factor: 6.518

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.